arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Cabaletta Bio, Inc.

CABA Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$3.48
▲ +0.3% Today
as of Sep 4, 16:46 ET
Last 30 days +27.57% Jul 27 → Sep 04
$2.54 $2.82 $3.09 $3.37 $3.65 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$3.48
High
$3.60
Low
$3.40
Volume
$5M
Avg Vol
$4M
Mkt Cap
$442M
P/E (TTM)
—
Beta
—
52w High
$4.23
52w Low
$1.56
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 2 items

Sep 1 · 12:00 PR GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences
Aug 13 · 11:30 PR GlobeNewswire
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Overview

52-week range
$1.56
$4.23
72% of range
Avg surprise (last 3)
-1.3%
Avg reaction (last 2)
+19.9%
100% positive
Latest IV / EM
129%
EM ±20.2% · $4 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.73$-0.63$-0.54$-0.44$-0.34 Actual $-0.45Actual $-0.37Actual $-0.37Actual $-0.51Actual $-0.56Actual $-0.62Actual $-0.71Est $-0.67Actual $-0.73Est $-0.71Actual $-0.44Actual $-0.39Est $-0.41Actual $-0.34 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-51M$-46M$-42M$-37M$-32M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.34 — — — — financials
Thu May 14, 2026Mar/2026 $-0.39 $-0.41 +4.9% +45.1% +0.6% earnings
Tue Sep 30, 2025Sep 2025 $-0.44 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.73 $-0.71 -2.8% — — earnings
Thu May 15, 2025Mar/2025 $-0.71 $-0.67 -6.0% — +39.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.62 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.56 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.51 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.37 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.37 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.45 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-52M$-44M—$-47M$-46M$-37M—$-33M
Net income$-51M$-44M—$-45M$-45M$-36M—$-31M
EPS (diluted)$-0.34$-0.39—$-0.44$-0.73$-0.71—$-0.62

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$225M$117M$83M$60M$146M$132M$164M$171M
Inventory————————
Total current assets$231M$122M$139M$165M$198M$135M$167M$186M
Total assets$257M$148M$165M$190M$224M$165M$185M$204M
Long-term debt————————
Total liabilities$46M$45M$53M$50M$46M$44M$33M$30M
Total equity$211M$103M$112M$139M$178M$122M$152M$174M

Implied volatility — last 90 days

42%143%244%345%446% Jun 07 — IV 117% · EM ±16.2%Jun 08 — IV 191% · EM ±25.2%Jun 09 — IV 167% · EM ±21.0%Jun 10 — IV 139% · EM ±16.4%Jun 11 — IV 105% · EM ±11.6%Jun 12 — IV 111% · EM ±11.3%Jun 16 — IV 120% · EM ±7.1%Jun 17 — IV 253% · EM ±10.6%Jun 19 — IV 76% · EM ±16.7%Jun 22 — IV 111% · EM ±23.3%Jun 23 — IV 89% · EM ±18.2%Jun 24 — IV 61% · EM ±12.2%Jun 25 — IV 74% · EM ±14.6%Jun 26 — IV 69% · EM ±13.3%Jun 29 — IV 127% · EM ±22.5%Jun 30 — IV 79% · EM ±13.7%Jul 01 — IV 75% · EM ±12.6%Jul 02 — IV 82% · EM ±13.3%Jul 03 — IV 85% · EM ±13.3%Jul 06 — IV 81% · EM ±11.3%Jul 07 — IV 85% · EM ±11.3%Jul 08 — IV 83% · EM ±10.4%Jul 09 — IV 95% · EM ±11.2%Jul 10 — IV 84% · EM ±9.2%Jul 13 — IV 150% · EM ±12.5%Jul 15 — IV 214% · EM ±12.6%Jul 16 — IV 447% · EM ±18.7%Jul 20 — IV 131% · EM ±30.9%Jul 21 — IV 80% · EM ±18.6%Jul 22 — IV 87% · EM ±20.0%Jul 23 — IV 83% · EM ±18.8%Jul 24 — IV 42% · EM ±9.3%Jul 27 — IV 84% · EM ±17.5%Jul 28 — IV 85% · EM ±17.4%Jul 29 — IV 74% · EM ±14.8%Jul 30 — IV 94% · EM ±18.4%Jul 31 — IV 88% · EM ±16.8%Aug 03 — IV 100% · EM ±17.7%Aug 05 — IV 44% · EM ±7.4%Aug 06 — IV 67% · EM ±10.9%Aug 11 — IV 81% · EM ±10.8%Aug 13 — IV 187% · EM ±22.1%Aug 14 — IV 395% · EM ±43.6%Aug 17 — IV 83% · EM ±6.9%Aug 18 — IV 70% · EM ±5.1%Aug 19 — IV 164% · EM ±9.7%Aug 24 — IV 100% · EM ±21.0%Aug 25 — IV 99% · EM ±20.2%Aug 26 — IV 88% · EM ±17.7%Aug 27 — IV 106% · EM ±20.7%Aug 28 — IV 91% · EM ±17.4%Aug 31 — IV 118% · EM ±20.9%Sep 01 — IV 128% · EM ±22.0%Sep 02 — IV 109% · EM ±18.2%Sep 04 — IV 129% · EM ±20.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in